Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Germans Trias i Pujol Hospital FUNDACIÓ LLUITA CONTRA LA SIDA |
---|---|
Information provided by: | Germans Trias i Pujol Hospital |
ClinicalTrials.gov Identifier: | NCT00356486 |
The purpose of this study is to compare the early virological response (EVR = undetectable [ribonucleic acid-hepatitis C virus] RNA-HCV or a reduction of > 2 log10) of patients with chronic hepatitis C coinfected with HIV treated with induction doses of peginterferon alpha-2a (40 KD) 270 µg/week and ribavirin 1600 mg/day for 4 weeks, followed by 8 weeks of treatment with peginterferon alpha-2a (40 KD) 180 µg/week and ribavirin 1000-1200 mg/day versus treatment with peginterferon alpha-2a (40 KD) 180 µg/week and ribavirin 1000-1200 mg/day for 12 weeks.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Peginterferon alfa-2a, Ribavirin, epoetin-β Drug: Peginterferon alfa-2a + Ribavirin for 12 weeks |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Open, Multicentre and Randomised Phase IV Study to Evaluate Viral Kinetics in the First 12 Weeks of Patients With Chronic Hepatitis C Genotypes 1 and 4 Coinfected by the Human Immunodeficiency Virus Treated With Induction Doses of Peginterferon Alpha-2a (40 KD) (270 μg/Week) and Ribavirin (1600 mg/Day) With Epoetin β Support (450 IU/kg/Week) |
Enrollment: | 74 |
Study Start Date: | October 2005 |
Study Completion Date: | March 2009 |
Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Peginterferon alfa-2a (40 KD) (270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (40 KD) (180 µg/week) + Ribavirin (1000-1200 mg/day) for 8 weeks |
Drug: Peginterferon alfa-2a, Ribavirin, epoetin-β
Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks |
B: Experimental
Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
|
Drug: Peginterferon alfa-2a + Ribavirin for 12 weeks
Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
|
This study seeks to ascertain whether treatment with higher doses of PEGASYS (270 µg/week) and ribavirin (1600 mg/day) for the first four weeks achieves the plasma concentrations of the product in the blood needed to reduce the half-life of the virions and accelerate the elimination thereof. This would bring the viral kinetic curves in coinfected patients closer to the model described for mono-infected HCV patients, probably achieving improved rates of response in week 12 (early virological response) and posterior in week 72 (sustained virological response). Therefore, the patients were randomised to treatment with two different doses, 270 µg and 180 µg of PEGASYS, and 1600 mg and 1000-1200 mg of ribavirin.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Spain | |
Hospital General Universitario de Alicante | |
Alicante, Spain, 46014 | |
Hospital del Mar | |
Barcelona, Spain, 08003 | |
Hospital Clínic i Provincial | |
Barcelona, Spain, 08036 | |
Hospital Ramón y Cajal | |
Madrid, Spain, 28007 | |
Hospital La Paz | |
Madrid, Spain, 28046 | |
Hospital Puerta del Mar | |
Cádiz, Spain, 11009 | |
Hospital Gregorio Marañón. | |
Madrid, Spain, 28007 | |
Hospital Clínico San Carlos | |
Madrid, Spain, 28040 | |
Spain, Barcelona | |
Hospital Germans Trias i Pujol, Badalona | |
Badalona, Barcelona, Spain, 08916 | |
Hospital General de Vic | |
Vic, Barcelona, Spain, 08500 | |
Consorci Sanitari de Terrassa | |
Terrassa, Barcelona, Spain, 08221 | |
Spain, Donostia | |
Hospital de Donostia | |
San Sebastián, Donostia, Spain, 20012 |
Principal Investigator: | Bonaventura Clotet, MD, PhD | LLuita contra la Sida Foundation-HIV Unit |
Responsible Party: | Lluita Sida Foundation ( Lluita Sida Foundation ) |
Study ID Numbers: | CORAL-2, 2004 - 000907 -16 |
Study First Received: | July 25, 2006 |
Last Updated: | September 2, 2009 |
ClinicalTrials.gov Identifier: | NCT00356486 History of Changes |
Health Authority: | Spain: Ministry of Health |
Chronic Hepatitis C Co-infection Induction dose HIV HIV Infections |
Antimetabolites Interferon-alpha Epoetin Alfa Anti-Infective Agents Sexually Transmitted Diseases, Viral Liver Diseases Hepatitis, Chronic Interferons Ribavirin Acquired Immunodeficiency Syndrome Hepatitis, Viral, Human Angiogenesis Inhibitors |
Antiviral Agents Immunologic Deficiency Syndromes Hepatitis Virus Diseases Digestive System Diseases HIV Infections Sexually Transmitted Diseases Peginterferon alfa-2a Hepatitis C Interferon Alfa-2a Hepatitis C, Chronic Retroviridae Infections |
Antimetabolites Anti-Infective Agents Sexually Transmitted Diseases, Viral Liver Diseases Slow Virus Diseases Hepatitis, Chronic Flaviviridae Infections Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Ribavirin Hepatitis, Viral, Human Infection Therapeutic Uses Growth Inhibitors |
Angiogenesis Modulating Agents Hepatitis C Retroviridae Infections RNA Virus Infections Immune System Diseases Growth Substances Acquired Immunodeficiency Syndrome Angiogenesis Inhibitors Antiviral Agents Pharmacologic Actions Immunologic Deficiency Syndromes Virus Diseases Hepatitis Digestive System Diseases HIV Infections |